WO2012165731A1 - 쌀, 쌀겨 또는 왕겨 추출물의 히스타민 수용체 길항제로서의 신규 용도 - Google Patents
쌀, 쌀겨 또는 왕겨 추출물의 히스타민 수용체 길항제로서의 신규 용도 Download PDFInfo
- Publication number
- WO2012165731A1 WO2012165731A1 PCT/KR2011/008374 KR2011008374W WO2012165731A1 WO 2012165731 A1 WO2012165731 A1 WO 2012165731A1 KR 2011008374 W KR2011008374 W KR 2011008374W WO 2012165731 A1 WO2012165731 A1 WO 2012165731A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rice
- extract
- rice bran
- sleep
- fraction
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/13—Preparation or pretreatment of starting material involving cleaning, e.g. washing or peeling
Definitions
- the present invention relates to a novel use of rice, rice bran or chaff extract as a histamine receptor antagonist, and also allergic rhinitis comprising rice, rice bran or chaff extract as an active ingredient; Inflammatory bowel disease; asthma; bronchitis; throw up; Stomach and duodenal ulcers; Gastroesophageal reflux; Sleep disorders; unrest; And to compositions for preventing or treating depression.
- Sleep accounts for one-third of human life and is the most fundamental and essential physiological phenomenon that is very important for health and mental stability.
- Chronic sleep deprivation and disability have a negative impact on overall physical and mental health, including cardiovascular disease and hypertension, memory and learning, metabolic control and weight, immunity and cancer resistance, diabetes, safety accidents, and mood.
- insomnia and 10% have chronic problems.
- insomnia due to anxiety symptoms.
- serotonin agonists and the like have been used, however, long-term use of such drugs has a severe problem of forming cognitive impairment, resistance, and dependency.
- antihistamines and natural herbal products are used as non-prescription sleep aids in the United States.
- antihistamines are representative ingredients of cold medicines as antagonists to histamine receptors. It's the only sleeping pill you can do.
- Histamine [2- (4-imidazolyl) ethylamine] is one of the functional neurotransmitters widely distributed throughout the body, such as the gastrointestinal tract [Burks 1994 in Johnson LR ed., Physiology of the Gastrointestinal Tract, Raven Press, NY, pp. 211-242. Histamine is known as gastric acid secretion, intestinal motility [Leurs et al., Br J. Pharmacol. 1991, 102, pp 179-185], vasomotor reactions, enteroinflammatory reactions and allergic reactions [Raithel et al., Int. Arch. Allergy Immunol.
- histamine mediates all its actions in both the central nervous system and peripheral regions through four families of histamine receptors, namely histamine H 1 , H 2 , H 3 and H 4 receptors.
- Histamine receptors act independently or in combination with H 1 , H 2 , H 3, and H 4 receptors, resulting in allergic and immune responses such as allergic rhinitis, inflammatory bowel disease, asthma, bronchitis, vomiting, gastric and secretory It is known to be associated with duodenal ulcer or gastroesophageal reflux, sedative and sleep induction in the brain.
- Rice is a valuable food resource, one of the world's three major grains, which half of the world's population uses as staple food, and is a key national resource that cannot be replaced by other crops, especially in Asia.
- Rice that has been stripped of rice husk, which is not the outer shell of rice, is called brown rice, and rice that has been polished with rice and stripped of rice bran and rice eyes is called rice.
- rice bran is an excellent ingredient in terms of nutrition despite being a by-product of polished rice.
- Rice bran (rice bran) contains about 95% of rice nutrients and contains high quality protein, dietary fiber, and various vitamins and minerals.
- the efficacy of rice bran has been shown to be anti-cancer, antioxidant, anti-inflammatory, anti-arteriosclerosis, cholesterol lowering, growth promotion, digestive function and immune strengthening.
- the correlation between rice, rice bran or rice husk and histamine receptor antagonists, further allergic rhinitis, allergic diseases such as asthma, diseases associated with excessive acid secretion, sleep, anxiety or depression have not been identified yet.
- the present invention provides a histamine receptor antagonist, which includes allergic rhinitis; Inflammatory bowel disease; asthma; bronchitis; throw up; Stomach and duodenal ulcers; Gastroesophageal reflux; Sleep disorders; unrest; And it aims to discover the components derived from natural products that can replace the existing drugs that have been used for the prevention or treatment of depression.
- the present invention is a novel use of rice, rice bran or rice husk extract as a histamine receptor antagonist, allergic rhinitis comprising rice, rice bran or rice husk extract as an active ingredient; Inflammatory bowel disease; asthma; bronchitis; throw up; Stomach and duodenal ulcers; Gastroesophageal reflux; Sleep disorders; unrest; And allergic rhinitis comprising administering to the subject a pharmaceutical composition for preventing or treating depression, a therapeutically effective amount of rice bran extract or rice bran powder; Inflammatory bowel disease; asthma; bronchitis; throw up; Stomach and duodenal ulcers; Gastroesophageal reflux; Sleep disorders; unrest; And methods for preventing or treating depression.
- Rice, rice bran or rice husk extract provides approximately the same level of diazepam, a drug used as a conventional sleep inducing agent, or improved sleep time, increased sleep duration, and increased nonram sleep, and is known as a histamine receptor antagonist.
- the sleep effect of maleate salt is completely inhibited by 2-pyridylethylamine dihydrochloride, which is a histamine receptor agonist, and the sleep effect of rice, rice bran or rice husk extract is suppressed, acting as a natural antihistamine. It is derived from rice, rice bran or rice husks and has no side effects that form cognitive impairment, tolerance or dependence even after prolonged use.
- FIG. 1 is a graph showing the effect of RWE on the elevation time of mice administered pentobarbital sleep dose (45 mg / kg, ip)
- Figure 2 is a pentobarbital sleep dose (45 mg / kg, ip) It is a graph showing the effect of RWE on the sleep time of the mice administered.
- Control group (0.5% CMC-saline 10 mL / kg), DZP (2 mg / kg) and RWE (50, 100, 250, 500 mg / kg) were orally administered (po) and pentobarbital was administered 45 minutes later.
- CON is the control; DZP stands for diazepam.
- Figure 3 is a graph showing the effect of REE on the elevation time of mice administered pentobarbital sleep dose (45 mg / kg, ip)
- Figure 4 is a pentobarbital sleep dose (45 mg / kg, ip) It is a graph showing the effect of REE on the sleep time of the mice administered.
- Control (0.5% CMC-saline 10 mL / kg), DZP (2 mg / kg) and REE (50, 100, 250, 500 mg / kg) were orally administered (po) and pentobarbital was administered 45 minutes later. .
- CON is the control; DZP stands for diazepam.
- Figure 5 is a graph showing the effect of HWE on the elevation of the mice administered pentobarbital sleep dose (45 mg / kg, ip)
- Figure 6 is a pentobarbital sleep dose (45 mg / kg, ip) It is a graph showing the effect of HWE on the sleep time of the mice administered.
- Control group (0.5% CMC-saline 10 mL / kg), DZP (2 mg / kg) and HWE (50, 100, 250, 500 mg / kg) were orally administered (po) and pentobarbital was administered 45 minutes later.
- CON is the control; DZP stands for diazepam.
- FIG. 7 is a graph showing the effect of HEE on the elevation time of the mice administered the pentobarbital sleeping dose (45 mg / kg, ip)
- Figure 8 is a pentobarbital sleeping dose (45 mg / kg, ip) It is a graph showing the effect of HEE on the sleep time of the mice administered.
- a control group (0.5% CMC-saline 10 mL / kg), DZP (2 mg / kg) and HEE (50, 100, 250, 500 mg / kg) were orally administered (po) and pentobarbital was administered 45 minutes later. .
- CON is the control; DZP stands for diazepam.
- FIG. 9 is a graph showing the effect of BWE on the elevation time of mice administered the pentobarbital sleeping dose (45 mg / kg, ip)
- Figure 10 is a pentobarbital sleeping dose (45 mg / kg, ip) It is a graph showing the effect of BWE on the sleep time of the mice administered.
- a control group (0.5% CMC-saline 10 mL / kg), DZP (2 mg / kg) and BWE (50, 100, 250, 500 mg / kg) were orally administered (po) and pentobarbital was administered 45 minutes later.
- CON is the control; DZP stands for diazepam.
- FIG 11 is a graph showing the effect of BEE on the elevation time of the mice administered the pentobarbital sleeping dose (45 mg / kg, ip)
- Figure 12 is a pentobarbital sleeping dose (45 mg / kg, ip) It is a graph showing the effect of BEE on the sleep time of the mice administered.
- a control group (0.5% CMC-saline 10 mL / kg), DZP (2 mg / kg) and BEE (50, 100, 250, 500 mg / kg) were orally administered (po) and pentobarbital was administered 45 minutes later.
- CON is the control; DZP stands for diazepam.
- FIG. 13 is a graph showing the effect of BEE-Wax on the elevation time of mice administered pentobarbital sleep dose (45 mg / kg, ip), and FIG. 14 is a pentobarbital sleep dose (45 mg / kg, ip).
- CON is the control; DZP stands for diazepam.
- FIG. 15 is a graph showing the effect of BEE-Oil on the elevation time of mice administered the pentobarbital sleep dose (45 mg / kg, ip), and FIG. 16 is a pentobarbital sleep dose (45 mg / kg, ip).
- * Indicates a significant difference at p ⁇ 0.05 compared to the control and ** at p ⁇ 0.01 compared to the control (Dunnet's test).
- CON is the control; DZP stands for diazepam.
- CON represents the control group.
- EtOH extract is ethyl acetate
- n-BuOH is n-butanol
- H2O represents distilled water.
- FIG 21 is a graph showing the effect of the BEE fraction on the elevation time of mice administered the pentobarbital sleeping dose (45 mg / kg, ip)
- Figure 22 is a pentobarbital sleeping dose (45 mg / kg, ip) It is a graph showing the effect of the BEE fraction on the sleep time of the mice administered.
- Control group (0.5% CMC- saline 10 mL / kg), DZP (2 mg / kg) BEE-H, BEE-B, BEE-W and BEE-E (50, 250 mg / kg) After 45 minutes pentobarbital was administered.
- CON is the control; DZP is diazepam; H is hexane extract; B is butanol extract; W is water extract; E stands for ethyl acetate extract.
- FIG. 23 shows a process for separating a subfraction of n-hexane extract from BEE.
- EtOAc is ethyl acetate; H2O represents distilled water.
- FIG. 24 is a graph showing the effect of the subfraction obtained from BEE-H on the elevation time of mice administered the pentobarbital sleep dose (45 mg / kg, ip)
- Figure 25 is a pentobarbital sleep dose (45 mg / kg, ip) is a graph showing the effect of the subfraction obtained from BEE-H on the sleep time of mice administered.
- Control group (0.5% CMC- saline 10 mL / kg), DZP (2 mg / kg) and BEE-H sub fraction (50 mg / kg) were orally administered (p.o.) and pentobarbital was administered 45 minutes later.
- C is a control; D represents diazepam.
- FIG. 26 is a graph showing the effect of subfractions obtained from BEE-H on elevation time of mice administered pentobarbital sleep dose (45 mg / kg, ip), and FIG. 27 is pentobarbital sleep dose (45 mg).
- / kg, ip) is a graph showing the effect of the subfraction obtained from BEE-H on the sleep time of mice administered.
- a control group (0.5% CMC- saline 10 mL / kg), DZP (2 mg / kg) and BEE-H sub fraction (250 mg / kg) were orally administered (p.o.) and pentobarbital was administered 45 min later.
- C is a control; D represents diazepam.
- FIG. 28 is a diagram illustrating a process of separating a small fraction of n-hexane extract from BEE.
- MeOH is methanol; EtOAc stands for ethyl acetate.
- FIG. 29 is a diagram illustrating a process of separating a small fraction of n-hexane extract.
- EtOAc is ethyl acetate
- CHCl 3 is chloroform
- MeOH is methanol
- H2O represents distilled water.
- FIG. 30 is a diagram illustrating a process of separating a small fraction of n-hexane extract.
- EtOAc is ethyl acetate
- CHCl 3 is chloroform
- MeOH stands for methanol.
- GPCR 31 is a graph showing the effect of the BEE-H-2 fraction on the activity of G-Protein Coupled receptor (GPCR).
- Figure 32 shows the elevation time according to the administration of histamine receptor agonists (PD) to the rice water extract (RWE) and the histamine receptor antagonist (PMS) of Preparation Example 1
- Figure 33 is the rice water of Preparation Example 1 It is a graph showing the sleep time according to administration of the histamine receptor agonist (PD) to the extract (RWE) and the antagonist (PMS) that acts on the histamine receptor.
- Controls CON, 0.5% CMC-saline 10 mL / kg
- RWE 500 mg / kg
- PMS 70 mg / kg
- * Indicates a significant difference at p ⁇ 0.05 compared to the control and ** at p ⁇ 0.01 compared to the control (Dunnet's test).
- Figure 34 shows the elevation time according to the administration of histamine receptor agonists (PD) to the rice bran ethanol extract (BEE) and the histamine receptor antagonist (PMS) of Preparation Example 3
- Figure 35 is bran ethanol of Preparation Example 3
- Controls CON, 0.5% CMC-saline 10 mL / kg
- BEE 500 mg / kg
- PMS 70 mg / kg
- FIG. 36 is a graph showing the elevation time of diazepam (DZP) and PMS according to the administration of histamine receptor agonist (PD)
- Figure 37 is the sleep of diazepam (DZP) and PMS according to the administration of histamine receptor agonist (PD) It is a graph showing time.
- the control group CON, 0.5% CMC-saline 10 mL / kg
- DZP (2 mg / kg)
- PMS 70 mg / kg
- PD (20 mg / kg) was intraperitoneally injected 10 minutes prior to oral PMS.
- * Indicates a significant difference at p ⁇ 0.05 compared to the control and ** at p ⁇ 0.01 compared to the control (Dunnet's test).
- FIG. 38 is a graph showing the elevation time of diazepam (DZP) and PMS according to the administration of flumazenyl (FLU), a GABAA-benzodiazepine antagonist
- FIG. 39 is a diazepam (DZP) according to the administration of flumazenyl (FLU).
- the control group CON, 0.5% CMC- saline 10 mL / kg
- BEE 500 mg / kg
- FLU (8 mg / kg) was intraperitoneally injected 10 minutes prior to oral administration of DZP, BEE.
- * Indicates a significant difference at p ⁇ 0.05 compared to the control and ** at p ⁇ 0.01 compared to the control (Dunnet's test).
- agonist unless otherwise indicated, interacts with histamine receptors, namely H 1 receptor, H 2 receptor, H 3 receptor, and H 4 receptor, thereby activating histamine receptor and physiological or pharmacological A substance that initiates a response characteristic, an "antagonist” competitively binds to the receptor at the same site as the agonist, but does not activate an intracellular response initiated by the active form of the receptor, thereby causing an intracellular response by the agonist Means that can suppress the material.
- histamine receptor antagonists including allergic rhinitis; Inflammatory bowel disease; asthma; bronchitis; throw up; Stomach and duodenal ulcers; Gastroesophageal reflux; Sleep disorders; unrest; And to prepare natural compositions that are highly effective in preventing or treating depression.
- the present invention was completed by elucidating that rice bran acts as a histamine receptor antagonist, and in particular, prevents or treats sleep disorders, anxiety or depression.
- the present invention is a novel use of rice, rice bran or rice husk extract as a histamine receptor antagonist, allergic rhinitis comprising rice, rice bran or rice husk extract as an active ingredient; Inflammatory bowel disease; asthma; bronchitis; throw up; Stomach and duodenal ulcers; Gastroesophageal reflux; Sleep disorders; unrest; And allergic rhinitis comprising administering to the subject a pharmaceutical composition for preventing or treating depression, a therapeutically effective amount of rice bran extract or rice bran powder; Inflammatory bowel disease; asthma; bronchitis; throw up; Stomach and duodenal ulcers; Gastroesophageal reflux; Sleep disorders; unrest; And methods for preventing or treating depression.
- the improvement, prevention or treatment of a sleep disorder may mean a decrease in time of sleep, an increase in sleep duration, or an increase in non-sleep sleep.
- rice, rice bran or rice husk extract exhibited approximately the same or improved reduction in elevation and increased duration of sleep compared to diazepam, a medicament conventionally used as a sleeping pill, anti-anxiety or antidepressant.
- pyrilamime maleate salt known as a histamine receptor antagonist
- 2-pyridylethylamine dihydrochloride a histamine receptor agonist
- rice, rice bran or chaff extracts are histamine receptor antagonists, including allergic rhinitis; Inflammatory bowel disease; asthma; bronchitis; throw up; Stomach and duodenal ulcers; Gastroesophageal reflux; Sleep disorders; unrest; And it can be used as an active ingredient of the composition for the prevention or treatment of depression, in particular useful as a composition for the prevention or treatment of sleep disorders, anxiety or depression.
- rice, rice bran or rice husk extract is harmless to the human body, which is approved as a food, has no side effects, and has an excellent effect of inducing sleep and prolonging sleep so as to prevent or treat sleep disorders, anxiety or depression. It can be usefully used.
- an experiment for anxiety or depression was not performed separately, but for example, components used for improving, preventing or treating sleep disorders, such as diazepam, may be used to improve anxiety or depression by changing a dose. It is well known to those skilled in the art that it can be used for prophylaxis or treatment.
- the rice, rice bran or chaff extract may be extracted using water, an organic solvent or a mixture thereof of rice bran as an extraction solvent.
- the kind of organic solvent used at this time and the mixing ratio of water and an organic solvent are not specifically limited.
- the organic solvent may be one or more solvents selected from the group consisting of lower alcohols, hexane, acetone, ethyl acetate, chloroform, and diethyl ether.
- the lower alcohol may be an alcohol having 1 to 6 carbon atoms.
- methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol, normal-butanol, 1-pentanol, 2-butoxyethanol or ethylene glycol may be used as the lower alcohol.
- Organic solvents include polar solvents such as acetic acid, dimethyl-formamide (DMFO) and dimethyl sulfoxide (DMSO), acetonitrile, ethyl acetate, methyl acetate, fluoroalkane, pentane, 2,2,4-trimethylpentane, and decane.
- polar solvents such as acetic acid, dimethyl-formamide (DMFO) and dimethyl sulfoxide (DMSO), acetonitrile, ethyl acetate, methyl acetate, fluoroalkane, pentane, 2,2,4-trimethylpentane, and decane.
- nonpolar solvents such as benzene, diethyl ether, diethyl sulfide, chloroform, dichloromethane, 1,2-dichloroethane, anneal, diethylamine, ether, carbon tetrachloride, and THF (Tetrahydrofuran).
- the rice, rice bran or chaff extract when extracting the rice, rice bran or chaff as an organic solvent, the rice, rice bran or chaff extract is separated into the supernatant and the lower layer, the supernatant is the oil fraction of the rice bran extract, the lower layer Corresponds to a common solvent extract.
- the lower layer is separated again by centrifugation or filter paper, it is divided into liquid and solid residues, which are wax fractions of rice, rice bran or rice husk extract. Therefore, the rice, rice bran or rice husk extract of the present invention is interpreted as a concept including all the oil fraction of rice, rice bran or rice husk extract, the liquid fraction of rice bran extract, the wax fraction of rice bran extract.
- the rice, rice bran or rice husk extract is any one or more selected from the group consisting of oil fraction of rice, rice bran or rice husk extract, liquid fraction of rice, rice bran or rice husk extract and wax fraction of rice, rice bran or rice husk extract It may include.
- the rice, rice bran or chaff extract may be a lower alcohol extract of rice bran, preferably an ethanol extract of rice, rice bran or chaff.
- the rice, rice bran or rice husk extract may be a hexane extract of rice, rice bran or rice husk. Hexane extract of rice, rice bran or rice husks is commonly used as 'rice bran oil'.
- the rice bran extract may be rice bran oil.
- the term 'extract' also includes fractions that additionally fractionate the extract. That is, rice, rice bran or rice husk extract is not only obtained by using the above-mentioned extraction solvent, but also includes those obtained by additionally applying a purification process.
- fractions obtained by passing the extract or fraction through an ultrafiltration membrane having a constant molecular weight cut-off value separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity), etc. Fractions obtained through the various purification methods described above are also included in the rice, rice bran or rice husk extract of the present invention.
- the rice, rice bran or chaff extract may be a fraction of the organic solvent extract of the rice bran re-fractionated with a second organic solvent.
- the organic solvent extract of rice, rice bran or rice husk is broadly defined as the oil fraction of rice, rice bran or rice husk extract, the liquid fraction of rice, rice bran or rice husk extract, and the wax fraction of rice, rice bran or rice husk extract. All are included, of which the term refers to the liquid fraction of rice, rice bran or rice husk extract.
- the fraction of the organic fraction of the rice, rice bran or rice husk re-fraction with a second organic solvent may mean a fraction of the liquid fraction of the rice bran extract with a second organic solvent.
- the rice, rice bran or chaff extract may be a fraction obtained by re-fractionation of the lower alcohol extract of rice, rice bran or chaff into a second organic solvent.
- the rice, rice bran or rice husk extract may be a fraction of the ethanol extract of rice, rice bran or rice husk re-fraction with hexane.
- fractions of rice, rice bran or rice husk extracts containing large amounts of fat-soluble components of rice, rice bran or rice husk show very good surface induction and sleep prolonging effects.
- extract as used herein referring to rice, rice bran or rice husk, as well as the crude extract obtained by treating the extraction solvent to rice bran, as well as processed products of rice, rice bran or rice husk extract.
- rice, rice bran or rice husk extract may be prepared in powder form by additional processes such as distillation under reduced pressure and freeze drying or spray drying.
- the rice, rice bran or rice husk extract of the present invention has a meaning broadly also includes a rice, rice bran or rice husk processed product, such as rice bran or rice husk powder formulated to administer the rice, rice bran or chaff itself to the animal. .
- a rice, rice bran or rice husk processed product such as rice bran or rice husk powder formulated to administer the rice, rice bran or chaff itself to the animal.
- the term 'comprising as an active ingredient' in the present specification means containing an amount sufficient to achieve the efficacy or activity of rice, rice bran or rice husk extract.
- the rice, rice bran or rice husk extract in the composition of the present invention is for example at least 0.001 mg / kg, preferably at least 0.1 mg / kg, more preferably at least 10 mg / kg, Even more preferably at least 100 mg / kg, even more preferably at least 250 mg / kg, most preferably at least 0.1 g / kg.
- rice, rice bran or rice husk extract is a natural product, even if it is excessively administered, there is no side effect to the human body, so that the upper limit of the amount of rice, rice bran or rice husk extract included in the composition of the present invention can be carried out by those skilled in the art.
- the pharmaceutical composition of the present invention may be prepared using a pharmaceutically suitable and physiologically acceptable adjuvant in addition to the active ingredient, and the adjuvant may include excipients, disintegrants, sweeteners, binders, coatings, swelling agents, lubricants, Lubricants, flavors and the like can be used.
- the pharmaceutical composition may be preferably formulated into a pharmaceutical composition comprising one or more pharmaceutically acceptable carriers in addition to the active ingredient described above for administration.
- Formulation forms of the pharmaceutical composition may be granules, powders, tablets, coated tablets, capsules, suppositories, solutions, syrups, juices, suspensions, emulsions, drops or injectable solutions.
- the active ingredient may be combined with an oral, nontoxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
- suitable binders, lubricants, disintegrants and coloring agents may also be included in the mixture.
- Suitable binders include but are not limited to natural and synthetic gums such as starch, gelatin, glucose or beta-lactose, corn sweeteners, acacia, trackercance or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride and the like.
- Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
- Acceptable pharmaceutical carriers in compositions formulated in liquid solutions are sterile and physiologically compatible, including saline, sterile water, Ringer's solution, buffered saline, albumin injectable solutions, dextrose solution, maltodextrin solution, glycerol, ethanol and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers and bacteriostatic agents may be added as necessary. Diluents, dispersants, surfactants, binders and lubricants may also be added in addition to formulate into injectable formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.
- the pharmaceutical composition of the present invention may be administered orally or parenterally, and in the case of parenteral administration, it may be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, and preferably, oral administration. .
- Suitable dosages of the pharmaceutical compositions of the invention vary depending on factors such as the formulation method, mode of administration, age, weight, sex, morbidity, condition of food, time of administration, route of administration, rate of excretion and response to reaction, Usually a skilled practitioner can easily determine and prescribe a dosage effective for the desired treatment or prophylaxis.
- the daily dose of the pharmaceutical composition of the present invention is 0.001-10 g / kg.
- compositions of the present invention may be prepared in unit dosage form by formulating with a pharmaceutically acceptable carrier and / or excipient according to methods which can be easily carried out by those skilled in the art. Or may be prepared by incorporation into a multi-dose container.
- the formulation may be in the form of a solution, suspension or emulsion in an oil or an aqueous medium, or may be in the form of extracts, powders, granules, tablets or capsules, and may further include a dispersant or stabilizer.
- the present invention also provides a food composition for preventing or improving sleep disorders, anxiety or depression comprising rice, rice bran or rice husk extract as an active ingredient.
- the food composition according to the present invention may be formulated in the same manner as the pharmaceutical composition, used as a functional food, or added to various foods.
- examples of the food to which the composition of the present invention may be added include beverages, alcoholic beverages, confectionary, diet bars, dairy products, meat, chocolates, pizza, ramen noodles, other noodles, gums, ice creams, vitamin complexes, and health supplements. Etc.
- the food composition of the present invention may include not only rice bran extract or rice bran powder as an active ingredient, but also components commonly added in food production, and include, for example, proteins, carbohydrates, fats, nutrients, seasonings, and flavoring agents. Include. Examples of the above carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And sugars such as conventional sugars such as polysaccharides such as dextrin, cyclodextrin and the like and xylitol, sorbitol, erythritol.
- natural flavoring agents such as tauumatin, stevia extract (for example rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used.
- the citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, and various plant extracts may be further included in addition to the rice, rice bran or chaff extract of the present invention. You can.
- the present invention provides a health functional food comprising a food composition for preventing or improving sleep disorders, anxiety or depression comprising the rice, rice bran or chaff extract as an active ingredient.
- Health functional food is a food prepared by adding rice bran extract or rice bran powder to food materials such as beverages, teas, spices, gums, confectionery, or by encapsulating, powdering, and suspension. Means to bring, but unlike the general medicine has the advantage that there is no side effect that can occur when taking a long-term use of the drug as a raw material.
- the health functional food of the present invention thus obtained is very useful because it can be consumed on a daily basis.
- the amount of the rice bran extract or the rice bran powder added in such a health functional food cannot be defined uniformly depending on the type of the health functional food, but may be added within a range that does not impair the original taste of the food. It is usually in the range of 0.01 to 50% by weight, preferably 0.1 to 20% by weight.
- a health functional food in the form of pills, granules, tablets or capsules it is usually added in the range of 0.1 to 100% by weight, preferably 0.5 to 80% by weight.
- the dietary supplement of the present invention may be in the form of pills, tablets, capsules or beverages.
- the invention also provides the use of rice, rice bran or rice husk extract for the manufacture of a medicament or food for the prevention, treatment or amelioration of sleep disorders, anxiety or depression.
- rice bran extract or rice bran powder may be used for the purpose of preventing, treating or improving sleep disorders, anxiety or depression.
- the invention also provides a method of preventing, treating or ameliorating sleep disorders, anxiety or depression comprising administering to a mammal an effective amount of rice, rice bran or rice husk extract.
- mammal refers to a mammal that is the subject of treatment, observation or experimentation, preferably human.
- the term “effective amount” means an amount of an active ingredient or pharmaceutical composition that induces a biological or medical response in a tissue system, animal or human, as contemplated by a researcher, veterinarian, doctor or other clinician, Amounts that induce alleviation of the symptoms of the disease or disorder. It will be apparent to those skilled in the art that the effective amount and frequency of administration for the active ingredients of the present invention will vary depending on the desired effect. Therefore, the optimal dosage to be administered can be readily determined by one skilled in the art and includes the type of disease, the severity of the disease, the amount of active ingredients and other ingredients contained in the composition, the type of formulation, and the age, weight, general health of the patient.
- the rice, rice bran or chaff extract in the case of an adult, when the rice, rice bran or chaff extract is administered once to several times a day, it is preferable to administer at a dose of 0.001 mg / kg to 10 g / kg.
- the composition comprising rice, rice bran or chaff extract as an active ingredient may be administered by oral, rectal, intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, transdermal, topical, intraocular or intradermal routes. It may be administered in a conventional manner.
- ICR mice (18-22 g, male) and SD rats (200-250 g, male) were distributed by Coatech Co., Ltd. and Orient Bio Co., Ltd. Used. Animals were kept under conditions of temperature 23 ⁇ 1 °C, humidity 55 ⁇ 5%, light-dark cycle (light: 9 am to 9 pm), illuminance of 3000 Lux. Feed and water were freely fed. All animals were managed according to the guidelines for the use of laboratory animals by the Korea Food Research Institutional Animal Care and Use Committee (KFRI-IACUC).
- EGE electroencephalogram
- EMG Electromyogram
- Rats were anesthetized with pentobarbital (50 mg / kg, i.p.) and the head fixed in a stereotaxic instrument. After dissection of the head subcutaneous connective tissue, a stainless-steel screw and a silver electrode line were inserted for EEG and EMG measurements. It was then fixed and sutured with dental cement. Disinfection of the surgical site and administration of antibiotics were performed for 3 days to prevent inflammation due to surgery and a recovery period of 7 days was allowed.
- CMC-saline solution used in the control group was orally administered (p.o.) 4 days before the measurement, and then a recording device was connected to induce compliance with the experimental procedure. After oral administration of the sample, it was stabilized for 5 minutes, followed by electroencephalogram (EEG) and electromyogram (EMG) for 6 hours from 10:00 to 16:00 using PAL-8200 series (Pinnacle Technology Inc, Oregon, USA). ] was measured. Sampling rates of EEG and EMG were set to 200 Hz (epoch time: 10 s), EEG set to 0.1-25 Hz, and EMG set filter areas of 10-100 Hz to record data.
- EEG electroencephalogram
- EMG electromyogram
- Sleep structure analysis was performed by FFT (Fast Fourier transform) algorithm, SleepSign program (Ver. 3.0, Kissei Comtec, Nagono, Japan) was used. The analysis results are divided into wake, REM sleep, rapid eye movement (theta band: 6-10 Hz), and nonrem sleep (NREM sleep, non-rapid eye movement, delta band: 0.65-4 Hz). It was. Elevation time was set to the time taken for 10 consecutive seconds of non remnant sleep in epoch units to appear more than 12 times.
- FFT Fast Fourier transform
- Rice water extract was prepared by adding 1 L of distilled water to 100 g of ground sample and heating it at 100 ° C. for 1 hour.
- Rice ethanol extract was added 10 times (w / v) of 70% ethanol to the ground sample. The extract was prepared in a 50 ° C. incubator for 1 day and sonicated three times for 90 minutes per day. All extracts were filtered and concentrated under reduced pressure, lyophilized, and powdered and used in the experiment.
- the yield of water extract (RWE) of rice was 1.16 wt%, and the yield of ethanol extract (REE) of rice was 0.19 wt%.
- Chaff water extract was prepared by adding 1 L of distilled water to 100 g of the ground sample and heating to 100 ° C. for 1 hour.
- the chaff ethanol extract (HEE) was added 10 times (w / v) of 70% ethanol to the ground sample.
- the extract was prepared in a 50 ° C. incubator for 1 day and sonicated three times for 90 minutes per day. All extracts were filtered and concentrated under reduced pressure, lyophilized, and powdered and used in the experiment.
- the yield of water extract (HWE) of rice husk was 5%, the yield of ethanol extract (HEE) of rice husk was 0.96%.
- Rice bran water extract was prepared by adding 1 L of distilled water to 100 g of the ground sample and heating to 100 ° C. for 1 hour. Rice ethanol extract (BEE) was added 10 times (w / v) of 70% ethanol to the ground sample. Prepared by extraction for 1 day in a 50 °C incubator. All extracts were filtered and concentrated under reduced pressure, lyophilized, and powdered and used in the experiment. The yield of water extract (BWE) of rice bran was 5.56%, and the yield of ethanol extract (BEE) of rice bran was 7.02%.
- BEE had a lot of oils in the extraction process, and in addition to BEE, two separate fractions could be identified. These were named BEE-Wax and BEE-Oil.
- rice bran ethanol extract BEE was divided into three types of manufacturing process. The first rice bran extract is divided into the supernatant and the lower layer. The supernatant is the oil fraction (BEE-Oil) of the rice bran extract, and the lower layer corresponds to the general ethanol extract. When the lower layer is separated again by centrifugation or filter paper, it is divided into a liquid phase (liquid fraction of rice bran extract) and a solid residue, and the residue corresponds to a wax fraction of rice bran extract (BEE-Wax).
- the water extract (RWE) and ethanol extract (REE) of Rice of Preparation Example 1 were orally administered (po) at concentrations of 50, 100, 250 and 500 mg / kg, and then pentobarbital (45 mg / kg, ip). Sleep induction effects were analyzed. As a result, as can be seen in Figures 1 and 2, rice water extract (RWE) showed a dose-dependent decrease in elevation and increase in sleep duration at concentrations other than 50 mg / kg ( p ⁇ 0.01). appear. In addition, as can be seen in Figures 3 and 4, the ethanol extract (REE) of rice also showed a dose-dependent decrease in elevation and sleep duration at concentrations other than 50 mg / kg. The increase in sleep duration was higher in rice ethanol extract (REE) than in rice water extract (RWE), and elevation time was similarly decreased in both rice water extract (RWE) and rice ethanol extract (REE). Indicated.
- the water extract (HWE) and ethanol extract (HEE) of Chaff of Preparation Example 2 were orally administered (po) at a concentration of 50, 100, 250 and 500 mg / kg, followed by pentobarbital (45 mg / kg, ip). Sleep induction effects were analyzed. As a result, as can be seen in Figures 5 and 6, the water extract (HWE) of the chaff showed a significant decrease in the elevation time, and sleep duration significantly at concentrations of 250 and 500 mg / kg Was significantly increased ( p ⁇ 0.01).
- the ethanol extract (HEE) of rice husks showed a significant decrease in elevation ( p ⁇ 0.01) at concentrations other than 50 mg / kg, dose-dependent There was an increase in sleep duration ( p ⁇ 0.01).
- the increase in sleep duration was higher in the ethanol extract (HEE) of the rice hull than the water extract of the rice hull (HWE), and the elevation time was similarly decreased in both the water extract (HWE) and the ethanol extract (HEE) of the rice hull. Indicated.
- BEE-Wax at a concentration of 50, 100, 250, and 500 mg / kg and BEE-Oil at a concentration of 500 and 1,000 mg / kg to confirm the effects of enhancing sleep induction of BEE-Wax and BEE-Oil.
- pentobarbital 45 mg / kg, ip
- BEE-Wax was able to confirm the surprising results.
- a dose-dependent decrease in elevation (p ⁇ 0.01) (FIG. 13) and an increase in sleep time ( p ⁇ 0.01) (FIG. 14) were shown, with decreased elevation and increased sleep time than BEE.
- the BEE-Oil concentration of 1,000 mg / kg showed a significant decrease in elevation time ( p ⁇ 0.01) (Fig. 15) and an increase in sleep time ( p ⁇ 0.01) (Fig. 16).
- the sleep induction effect is not greater than that of BEE and BEE-Wax, the sleep-promoting effect was also confirmed in BEE-Oil, and BEE-Wax is expected to have a great ripple effect in the future.
- Elevation time and total sleep time after oral administration of BEE 500 mg / kg are shown in FIG. 17.
- the average elevation time of the control group was 31.9 minutes and the elevation of BEE was reduced to 26.2 minutes by 5.7 minutes.
- the total sleep time was 165.4 minutes for the control group and 83 minutes increased to 248.6 minutes when orally administered BEE 500 mg / kg.
- the awakening, RAM and non-RAM time of the SD rats were analyzed and shown in FIG. 18.
- the arousal decreased relatively
- the non-rem of the control group was 153.8 minutes
- the BEE 500 mg / kg non-rem increased by about 23 minutes to 234.8 minutes
- most of the increase in total sleep time was non-rem. .
- the ratio of arousal, nonremem and rem each hour during the measurement of EEG of rats after oral administration of BEE 500 mg / kg is shown in FIG. 19.
- the nonrem increased significantly for 3 hours after oral administration, and then decreased slightly and then increased again. This led to sleep as BEE was digested during the first 3 hours, and the overall non-rem ratio was greater than the control group at all times, indicating that the sleep effect continued for 6 hours. Although BEE did not significantly shorten sleep induction time, it seems that the duration of sleep was increased as the total sleep time increased.
- BEE liquid fraction of rice bran ethanol extract of Preparation Example 3 was separated and purified using four solvents of hexane, butanol, water and ethyl acetate in order to obtain a more accurate single sleep-inducing substance using BEE having a large amount of oils.
- BEE-E ethyl acetate
- BEE-W water
- BEE-H hexane
- BEE-B butanol
- BEE-H and BEE-B butanol
- BEE-B butanol
- Pentobarbital after oral administration (po) at 50 mg / kg and 250 mg / kg concentrations to confirm the sleep-induced enhancement effect of BEE-H-1 to BEE-H-11, a subfraction of the BEE-H fraction (45 mg / kg, ip) was injected intraperitoneally to determine the changes in elevation and sleep time.
- BEE-H-1 to BEE-H-12 A small fraction of BEE-H gave a total of 12 fractions (BEE-H-1 to BEE-H-12). In vivo activity test for these showed high activity in BEE-H-2, BEE-H-10 and BEE-H-11 fractions, among which the preparation of the second small fraction of BEE-H-2 Proceeded.
- BEE-H-1 A small fraction of BEE-H gave a total of 12 fractions (BEE-H-1 to BEE-H-12).
- BEE-H-2, BEE-H-10 and BEE-H-11 fractions showed high activity results, among which the preparation of the second small fraction of BEE-H-10 Proceeded.
- BEE-H-1 to BEE-H-12 A small fraction of BEE-H gave a total of 12 fractions (BEE-H-1 to BEE-H-12).
- BEE-H-2, BEE-H-10, and BEE-H-11 fractions showed high activity results.
- the second small fraction of BEE-H-11 was prepared. Proceeded.
- histamine receptor antagonists sleep-inducing effects of histamine receptor antagonists are inhibited by histamine receptor agonists.
- histamine receptor agonists the mechanism of action of rice bran ethanol extract using the antagonist (pyrilamine maleate salt, PMS) and agonist (2-pyridylethylamine dihydrochloride, PD) acting on the histamine receptor.
- rice water extract (RWE) and rice bran ethanol extract (BEE) were 500 mg / kg and antagonist PMS were 70 mg / kg, respectively. 45 minutes prior to oral administration (hypnotic dosage 45 mg / kg), agonist PD received 20 mg / kg of BEE, PMS orally 10 minutes before oral administration for sleep latency and sleep duration. ) was measured.
- diazepam which is one of the representative agonists PD
- DZP diazepam
- DZP a well-known GABAA-benzodiazepine active agonist
- antagonist PMS was orally administered 70 mg / kg 45 minutes prior to pentobarbital administration (hypnotic dosage 45 mg / kg)
- histamine receptor agonist PD 20 mg / kg or GABAA-benzodiazepine antagonist
- Flumagzenyl (FLU) 8 mg / kg was intraperitoneally injected 10 minutes prior to oral administration of DZP, BEE and PMS to measure sleep latency and sleep duration.
- PD a histamine receptor agonist
- DZP elevation time or sleep period of diazepam
- GABAA Flumazenyl a benzodiazepine antagonist
- rice bran ethanol extract (BEE) has a sleep effect by antagonizing histamine receptors, not GABAA-benzodiazepine receptor binding.
- rice, rice bran or rice husk extract of the present invention is an antihistamine as a sleep disorder; unrest; And prevention or treatment of depression, as well as allergic rhinitis; Inflammatory bowel disease; asthma; bronchitis; throw up; Stomach and duodenal ulcers; It will be useful as a natural medicine or food effective for the prevention and treatment of diseases mediated by histamine receptors such as gastroesophageal reflux.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims (19)
- 쌀, 쌀겨 또는 왕겨 추출물을 유효성분으로 포함하는 히스타민 수용체 활성 저해용 약제학적 조성물.
- 제1항에 있어서,상기 히스타민 수용체 활성 저해용 약제학적 조성물은 알레르기성 비염; 염증성 장질환; 천식; 기관지염; 구토; 위 및 십이지장 궤양; 위식도 역류; 수면장애; 불안; 및 우울증의 예방 또는 치료를 위한 것을 특징으로 하는 히스타민 수용체 활성 저해용 약제학적 조성물.
- 제2항에 있어서,상기 수면 장애의 예방 또는 치료는 입면 시간의 감소, 수면 지속 시간의 증가 또는 논램 수면의 증가를 위한 것을 특징으로 하는 히스타민 수용체 활성 저해용 약제학적 조성물.
- 제1항에 있어서,상기 쌀, 쌀겨 또는 왕겨 추출물은 쌀, 쌀겨 또는 왕겨의 물, 유기용매 또는 이들의 혼합물의 추출물인 것을 특징으로 하는 히스타민 수용체 활성 저해용 약제학적 조성물.
- 제4항에 있어서,상기 유기용매는 저급 알코올, 헥산, 아세톤, 에틸 아세테이트, 클로로포름, 및 디에틸에테르로 이루어진 군으로부터 선택된 하나 이상의 용매인 것을 특징으로 하는 히스타민 수용체 활성 저해용 약제학적 조성물.
- 제5항에 있어서,상기 유기용매는 에탄올인 것을 특징으로 하는 히스타민 수용체 활성 저해용 약제학적 조성물.
- 제1항에 있어서,상기 쌀, 쌀겨 또는 왕겨 추출물은 쌀, 쌀겨 또는 왕겨 추출물의 오일 분획, 쌀, 쌀겨 또는 왕겨 추출물의 액상 분획 및 쌀, 쌀겨 또는 왕겨 추출물의 왁스 분획으로 이루어진 군으로부터 선택된 어느 하나 이상을 포함하는 것을 특징으로 하는 히스타민 수용체 활성 저해용 약제학적 조성물.
- 제7항에 있어서,상기 쌀겨 추출물의 오일 분획은 쌀겨유인 것을 특징으로 하는 히스타민 수용체 활성 저해용 약제학적 조성물.
- 제 1 항에 있어서,상기 쌀, 쌀겨 또는 왕겨 추출물은 쌀, 쌀겨 또는 왕겨의 유기용매 추출물을 제2의 유기용매로 재분획한 분획물인 것을 특징으로 하는 히스타민 수용체 활성 저해용 약제학적 조성물.
- 제1항에 있어서,상기 쌀, 쌀겨 또는 왕겨 추출물은 쌀겨의 저급 알코올 추출물을 제2의 유기용매로 재분획한 분획물인 것을 특징으로 하는 히스타민 수용체 활성 저해용 약제학적 조성물.
- 제1항에 있어서,상기 쌀, 쌀겨 또는 왕겨 추출물은 쌀겨의 에탄올 추출물을 헥산으로 재분획한 분획물인 것을 특징으로 하는 히스타민 수용체 활성 저해용 약제학적 조성물.
- 쌀, 쌀겨 또는 왕겨 추출물을 유효성분으로 포함하는 히스타민 수용체 활성 저해를 통한 수면 장애, 불안 또는 우울증의 예방 또는 개선용 식품 조성물.
- 제12항에 있어서,상기 수면 장애의 예방 또는 개선은 입면 시간의 감소, 수면 지속 시간의 증가 또는 논램 수면의 증가를 위한 것을 특징으로 하는 수면 장애, 불안 또는 우울증의 예방 또는 개선용 식품 조성물.
- 제12항에 있어서,상기 쌀, 쌀겨 또는 왕겨 추출물은 쌀, 쌀겨 또는 왕겨의 물, 유기용매 또는 이들의 혼합물의 추출물인 것을 특징으로 하는 수면 장애, 불안 또는 우울증의 예방 또는 개선용 식품 조성물.
- 제13항에 있어서,상기 유기용매는 저급 알코올, 헥산, 아세톤, 에틸 아세테이트, 클로로포름, 및 디에틸에테르로 이루어진 군으로부터 선택된 하나 이상의 용매인 것을 특징으로 하는 수면 장애, 불안 또는 우울증의 예방 또는 개선용 식품 조성물.
- 제15항에 있어서,상기 유기용매는 에탄올인 것을 특징으로 하는 수면 장애, 불안 또는 우울증의 예방 또는 개선용 식품 조성물.
- 제12항에 있어서,상기 쌀, 쌀겨 또는 왕겨 추출물은 쌀, 쌀겨 또는 왕겨 추출물의 오일 분획, 쌀, 쌀겨 또는 왕겨 추출물의 액상 분획 및 쌀, 쌀겨 또는 왕겨 추출물의 왁스 분획으로 이루어진 군으로부터 선택된 어느 하나 이상을 포함하는 것을 특징으로 하는 수면 장애, 불안 또는 우울증의 예방 또는 개선용 식품 조성물.
- 제17항에 있어서,상기 쌀겨 추출물의 오일 분획은 쌀겨유인 것을 특징으로 하는 수면 장애, 불안 또는 우울증의 예방 또는 개선용 식품 조성물.
- 제12항에 있어서,상기 쌀, 쌀겨 또는 왕겨 추출물은 쌀, 쌀겨 또는 왕겨의 에탄올 추출물을 헥산으로 재분획한 분획물인 것을 특징으로 하는 수면 장애, 불안 또는 우울증의 예방 또는 개선용 식품 조성물.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2011369552A AU2011369552A1 (en) | 2011-05-27 | 2011-11-04 | Novel use of rice, rice bran or rice hull extract as an histamine receptor antagonist |
EP11866924.1A EP2716296B1 (en) | 2011-05-27 | 2011-11-04 | Novel usage of rice bran, or rice hull extract as histamine receptor antagonist |
CA2837046A CA2837046A1 (en) | 2011-05-27 | 2011-11-04 | Novel use of rice, rice bran or rice hull extract as a histamine receptor antagonist |
JP2014512744A JP6076335B2 (ja) | 2011-05-27 | 2011-11-04 | ヒスタミン受容体活性阻害用の薬剤学的組成物、及び、睡眠障害、不安またはうつ病の予防または改善用食品組成物 |
CN201180071169.0A CN103561755A (zh) | 2011-05-27 | 2011-11-04 | 稻米、米糠或稻壳提取物作为组胺受体拮抗剂的新用途 |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2011-0050474 | 2011-05-27 | ||
KR1020110050472A KR101336411B1 (ko) | 2011-05-27 | 2011-05-27 | 쌀 추출물의 수면 장애, 불안 또는 우울증의 개선, 예방 또는 치료를 위한 신규 용도 |
KR10-2011-0050472 | 2011-05-27 | ||
KR1020110050474A KR101336502B1 (ko) | 2011-05-27 | 2011-05-27 | 쌀겨 추출물 또는 쌀겨 분말의 수면 장애, 불안 또는 우울증의 개선, 예방 또는 치료를 위한 신규 용도 |
KR1020110056624A KR101351883B1 (ko) | 2011-06-13 | 2011-06-13 | 왕겨 추출물의 수면 장애, 불안 또는 우울증의 개선, 예방 또는 치료를 위한 신규 용도 |
KR10-2011-0056624 | 2011-06-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012165731A1 true WO2012165731A1 (ko) | 2012-12-06 |
Family
ID=47259550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/008374 WO2012165731A1 (ko) | 2011-05-27 | 2011-11-04 | 쌀, 쌀겨 또는 왕겨 추출물의 히스타민 수용체 길항제로서의 신규 용도 |
Country Status (8)
Country | Link |
---|---|
US (2) | US20130171280A1 (ko) |
EP (1) | EP2716296B1 (ko) |
JP (1) | JP6076335B2 (ko) |
KR (1) | KR101336411B1 (ko) |
CN (1) | CN103561755A (ko) |
AU (1) | AU2011369552A1 (ko) |
CA (1) | CA2837046A1 (ko) |
WO (1) | WO2012165731A1 (ko) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160165941A1 (en) | 2014-11-21 | 2016-06-16 | Flipn'Sweet, LLC | Sugar substitute compositions comprising digestion resistent soluble fiber |
CN107184834A (zh) * | 2017-05-22 | 2017-09-22 | 辽宁大学 | 含有稻壳黄酮的抗抑郁保健品 |
CN107156842A (zh) * | 2017-05-22 | 2017-09-15 | 辽宁大学 | 含有稻壳黄酮的抗乳腺癌保健品 |
CN106983830A (zh) * | 2017-05-22 | 2017-07-28 | 辽宁大学 | 含有米糠黄酮的抗抑郁保健品 |
WO2018229776A1 (en) | 2017-06-15 | 2018-12-20 | Better Than Sweet Ltd. | Dairy-based sugar substitute |
CN107259308B (zh) * | 2017-06-23 | 2020-07-03 | 贺州学院 | 一种植物源鲜切荸荠黄化抑制剂及其制备和应用方法 |
KR101912814B1 (ko) | 2018-08-31 | 2018-10-29 | 한국식품연구원 | 쌀겨 추출물 분말의 제조방법 |
EP3869976A4 (en) * | 2018-10-25 | 2022-08-10 | HOFMEKLER, Ori | NATURAL SWEETING FLAVOR COMPOSITION |
CN109907319A (zh) * | 2019-03-12 | 2019-06-21 | 中南林业科技大学 | 一种米糠提取物及其制备方法和在保健食品中的应用 |
KR102422965B1 (ko) | 2022-04-21 | 2022-07-20 | 재단법인 전남바이오산업진흥원 | 감탕나무(Ilex integra Thunb.) 잎 추출물을 포함하는 수면장애 예방 또는 개선용 조성물 |
CN116392554A (zh) * | 2023-04-23 | 2023-07-07 | 昆明理工大学 | 红米种皮活性成分在制备防治溃疡性结肠炎药物中的应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3678436B2 (ja) * | 1993-02-16 | 2005-08-03 | 株式会社創研 | 抗潰瘍剤 |
JP3015913B1 (ja) * | 1998-10-16 | 2000-03-06 | 工業技術院長 | 生理活性米糠油の増収法 |
JP3416104B2 (ja) * | 1999-12-20 | 2003-06-16 | 雪印食品株式会社 | 食品の抗酸化能を増強させる方法及び食品用の抗酸化能増強剤 |
JP2001240859A (ja) * | 2000-02-28 | 2001-09-04 | Snow Brand Food Co Ltd | 肉から得られる抗酸化性物質及びその使用方法 |
CN1232539C (zh) * | 2002-05-10 | 2005-12-21 | 刘云清 | 有机药物与倍他环糊精衍生物的配合物及其制备方法 |
AU2003256104A1 (en) * | 2002-08-14 | 2004-03-03 | Bionutrigen Co., Ltd | Powder or extracts of plant leaves with anti-obesity effects and anti-obesity food comprising them |
US20050249823A1 (en) * | 2003-11-04 | 2005-11-10 | Murphy Tanya K | Methods for the prevention or amelioration of neuropsychiatric and related diseases |
JP4411117B2 (ja) * | 2004-03-25 | 2010-02-10 | エスエス製薬株式会社 | 睡眠改善医薬組成物 |
JP4754384B2 (ja) * | 2006-03-30 | 2011-08-24 | 株式会社バンダイナムコゲームス | プログラム、情報記録媒体および画像生成システム |
JP5118863B2 (ja) * | 2006-03-31 | 2013-01-16 | 第一三共ヘルスケア株式会社 | 催眠用医薬組成物 |
JP5349290B2 (ja) * | 2006-04-03 | 2013-11-20 | オディディ,イサ | 薬物送達組成物およびそれを含む医薬品、ならびにその製造方法 |
JP2008295380A (ja) * | 2007-05-31 | 2008-12-11 | Ikari Super Market:Kk | ギャバ含有食品素材およびその製造方法 |
KR100905747B1 (ko) * | 2007-07-13 | 2009-07-01 | 고려대학교 산학협력단 | 안토시아닌을 함유하는 비스테로이드성 항염증제에 의해유발된 위염 및 위궤양 치료용 조성물 |
JP5380930B2 (ja) * | 2007-07-24 | 2014-01-08 | 大正製薬株式会社 | 睡眠改善剤 |
KR100963339B1 (ko) * | 2008-04-02 | 2010-06-14 | 다산엠앤에프(주) | 쌀 프롤라민을 포함하는 항소화성궤양 조성물 |
CN101608156A (zh) * | 2008-06-17 | 2009-12-23 | 王茂芝 | 一种养生保健酒 |
KR101041044B1 (ko) * | 2008-09-10 | 2011-06-13 | 우석대학교 산학협력단 | 불면 증상의 예방 및 개선용 조성물과 그의 제조방법 |
CN101538519B (zh) * | 2009-04-29 | 2012-10-03 | 湛江师范学院 | 纯天然双蛹保健米酒及其制备方法 |
CN101869237A (zh) * | 2010-06-04 | 2010-10-27 | 刘小松 | 一种带有原花青素和花青素的米面淀粉食品 |
CN101884640B (zh) * | 2010-07-01 | 2012-04-18 | 北京世纪博康医药科技有限公司 | 谷维素的用途 |
CN101912115B (zh) * | 2010-08-04 | 2012-05-02 | 安徽燕之坊食品有限公司 | 一种改善睡眠的营养米及其加工方法 |
-
2011
- 2011-05-27 KR KR1020110050472A patent/KR101336411B1/ko active IP Right Grant
- 2011-11-04 CA CA2837046A patent/CA2837046A1/en not_active Abandoned
- 2011-11-04 JP JP2014512744A patent/JP6076335B2/ja active Active
- 2011-11-04 WO PCT/KR2011/008374 patent/WO2012165731A1/ko active Application Filing
- 2011-11-04 EP EP11866924.1A patent/EP2716296B1/en active Active
- 2011-11-04 CN CN201180071169.0A patent/CN103561755A/zh active Pending
- 2011-11-04 AU AU2011369552A patent/AU2011369552A1/en not_active Abandoned
- 2011-11-07 US US13/290,357 patent/US20130171280A1/en not_active Abandoned
-
2015
- 2015-07-21 US US14/804,598 patent/US20150320823A1/en not_active Abandoned
Non-Patent Citations (11)
Title |
---|
BURKS: "Physiology of the Gastrointestinal Tract", 1994, RAVEN PRESS, pages: 211 - 242 |
HYUN IM CHOI ET AL.: "Anticancer (in vitro) and Antiallergy Effects of Rice Bran Extracts", JOURNAL OF THE KOREAN SOCIETY OF FOOD SCIENCE AND NUTRITION, vol. 35, no. 10, 2006, pages 1297 - 1303, XP053026450 * |
INAGAKI ET AL., J. COMP. NEUROL., vol. 273, 1988, pages 283 - 300 |
KIM, H-M. ET AL.: "The evaluation of the antianaphylactic effect of Oryza Sativa L. subsp. Hsien ting in Rats", PHARMACOLOGICAL RESEARCH, vol. 40, no. 1, 1999, pages 31 - 36, XP009101721 * |
LEE, S-H. ET AL.: "Inhibitory effect of DA-9201, an extract of Oryza sativa L., on airway inflammation and bronchial hyperresponsiveness in mouse asthma model", BIOLOGICAL AND PHARMACEUTICAL BULLETIN, vol. 29, no. 6, 2006, pages 1148 - 1153, XP055135717 * |
LEURS ET AL., BR. J. PHARMACOL., vol. 102, 1991, pages 179 - 185 |
PANULA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 2572 - 2576 |
PASSANI, M. B. ET AL.: "Histamine receptors in the CNS as targets for therapeutic intervention", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 32, no. 4, April 2011 (2011-04-01), pages 242 - 249, XP028196562 * |
RAITHEL ET AL., INT. ARCH. ALLERGY IMMUNOL., vol. 108, 1995, pages 127 - 133 |
See also references of EP2716296A4 |
SUN PHIL CHOI ET AL.: "Inhibitory Activity of Pigmented Rice Bran Extract to the Allergic Inflammation in Basophilic Cell Line and Peritoneal Mast Cells", JOURNAL OF THE KOREAN SOCIETY FOR APPLIED BIOLOGICAL CHEMISTRY, vol. 48, no. 4, 2005, pages 315 - 321, XP053021132 * |
Also Published As
Publication number | Publication date |
---|---|
CN103561755A (zh) | 2014-02-05 |
KR101336411B1 (ko) | 2013-12-04 |
EP2716296B1 (en) | 2017-04-26 |
JP2014516052A (ja) | 2014-07-07 |
EP2716296A1 (en) | 2014-04-09 |
EP2716296A4 (en) | 2014-10-29 |
JP6076335B2 (ja) | 2017-02-08 |
AU2011369552A1 (en) | 2013-12-12 |
CA2837046A1 (en) | 2012-12-06 |
US20130171280A1 (en) | 2013-07-04 |
US20150320823A1 (en) | 2015-11-12 |
KR20120132652A (ko) | 2012-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012165731A1 (ko) | 쌀, 쌀겨 또는 왕겨 추출물의 히스타민 수용체 길항제로서의 신규 용도 | |
WO2010036052A2 (ko) | 4-o-메틸호노키올을 함유하는 아밀로이드 관련 질환의 치료 또는 예방용 조성물 | |
WO2017014502A1 (ko) | 해당화 꽃 추출물을 유효성분으로 포함하는 il-6 매개성 질환의 예방 또는 치료용 약학적 조성물 | |
WO2016153211A2 (ko) | 감귤류 과피 추출물의 제조방법 및 간 손상 예방, 개선 또는 치료용 조성물 | |
WO2013100340A1 (ko) | 황칠나무 추출물을 포함하는 남성 성기능 개선용 조성물 | |
KR101336502B1 (ko) | 쌀겨 추출물 또는 쌀겨 분말의 수면 장애, 불안 또는 우울증의 개선, 예방 또는 치료를 위한 신규 용도 | |
WO2023136428A1 (ko) | 효소처리된 아쉬아간다 추출물을 유효성분으로 함유하는 수면장애 예방 또는 치료용 조성물 | |
WO2019209061A1 (ko) | 총백을 유효성분으로 포함하는 뼈 성장 촉진용 조성물 | |
WO2019103497A1 (ko) | 천연추출물을 포함하는 소양증의 예방 또는 치료용 조성물 | |
WO2014157803A1 (ko) | 패류 추출물을 유효성분으로 포함하는 불안 완화, 경련 개선, 진정 작용, 또는 수면 유도 또는 개선용 조성물 | |
WO2018208107A1 (ko) | 플로로글루시놀을 유효성분으로 하는 수면 장애 개선, 예방 또는 치료용 조성물, 또는 gaba-a 수용체 벤조다이아제핀 결합 위치 효능제의 내성 억제 또는 부작용 경감용 조성물 | |
WO2014069836A1 (ko) | 폴리코사놀을 유효성분으로 하는 히스타민 수용체 길항제 조성물 | |
WO2017111429A1 (ko) | 들쭉 추출물을 유효성분으로 포함하는 안구건조증 치료용 조성물 | |
WO2013005956A2 (ko) | 위장관 운동장애 예방 및 개선용 약학 조성물 그리고 식품 조성물 | |
WO2019031655A1 (ko) | 티몰을 유효성분으로 함유하는 피부 주름 또는 아토피성 피부염의 예방 또는 치료용 조성물 | |
WO2014069837A1 (ko) | 감마오리자놀을 유효성분으로 하는 히스타민 수용체 길항제 조성물 | |
KR101444098B1 (ko) | 쌀, 쌀겨 또는 왕겨 추출물의 히스타민 수용체 길항제로서의 신규 용도 | |
WO2019208914A1 (ko) | 마치현을 유효성분으로 포함하는 뼈 성장 촉진용 조성물 | |
KR101303713B1 (ko) | 백하수오, 구절초 또는 측백엽 추출물을 포함하는 수면 장애의 예방 또는 치료용 조성물 | |
WO2023043169A1 (ko) | 쑥 및 삼백초 혼합 추출물을 포함하는 미세먼지로 인한 염증성 질환 예방 또는 치료용 조성물 | |
WO2023121300A1 (ko) | 로스팅된 감귤류 부산물의 추출물을 유효성분으로 포함하는 수면장애 또는 불면증의 예방, 개선 또는 치료용 조성물 | |
WO2021187679A1 (ko) | 해삼 유래 사포닌 화합물을 포함하는 신경병증의 예방, 완화 또는 치료용 조성물 | |
KR101351883B1 (ko) | 왕겨 추출물의 수면 장애, 불안 또는 우울증의 개선, 예방 또는 치료를 위한 신규 용도 | |
WO2022169254A1 (ko) | 장내 미생물 또는 이로부터 유래된 세포밖 소포체를 유효성분으로 포함하는 수면장애의 예방, 개선 또는 치료용 조성물 | |
WO2023136526A1 (ko) | 말차 추출물을 유효성분으로 포함하는 만성스트레스로 인한 우울증 및 불안장애의 예방, 개선 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11866924 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014512744 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2837046 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2011369552 Country of ref document: AU Date of ref document: 20111104 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2011866924 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011866924 Country of ref document: EP |